Dermatology Times: Alphyn Expands Pipeline with Phase 2 Trial of Zabalafin Hydrogel for Molluscum Contagiosum by Marie Bosslett NEWS PROVIDED BY Alphyn Biologics February 19, 2026 Alphyn Biologics advances zabalafin hydrogel for MC, aiming for painless relief by clearing lesions and itch in pediatric patients. Read the Dermatology Times article here. CONTACTS Corporate: Neal Koller…
Dermatology Times: New Research Highlights Zabalafin Hydrogel’s Novel Multitargeted Approach to AD Treatment by Marie Bosslett NEWS PROVIDED BY Alphyn Biologics July 2, 2025 A new paper highlights Alphyn Biologics’ Zabalafin Hydrogel as a promising multitarget therapy for atopic dermatitis, addressing inflammation, itch, and bacterial complications. Read the Dermatology Times article here. CONTACTS Corporate: Neal…
Dermatology Times: Alphyn Doses First Patient in Phase 2b Trial for Zabalafin Hydrogel by Emma Andrus NEWS PROVIDED BY Alphyn Biologics April 8, 2025 Alphyn Biologics has dosed the first patient in a global phase 2b trial of zabalafin hydrogel for mild to moderate atopic dermatitis. Read the Dermatology Times article here. CONTACTS Corporate: Neal…
Clinical Trials Arena: Alphyn prepares for two global trials in atopic dermatitis by Urtė Fultinavičiūtė NEWS PROVIDED BY Alphyn Biologics July 26, 2023 Alphyn is planning to open sites in the US, Canada, Europe and Australia. Read the Clinical Trials Arena article here. CONTACTS Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687 Media: Susan Thomas…
Healio: Interim results show AB-101a significantly controls atopic dermatitis skin bacteria by Gabrielle Capaldo NEWS PROVIDED BY Alphyn Biologics July 17, 2023 80% of patients achieved an itch score improvement of 4 points or more. 90% of patients achieved EASI 50 and 44% achieved EASI 75. Read the Healio article here. CONTACTS Corporate: Neal…